Mantle cell lymphoma (MCL) is a rare type of B-cell non-Hodgkin lymphoma that usually develops in lymph nodes but can also affect the bone marrow, spleen, blood, and digestive tract. MCL can behave aggressively, although some cases progress more slowly. Treatment depends on disease stage, symptoms, overall health, age, and specific biological characteristics of the lymphoma. Advances in targeted therapies, immunotherapy, cellular therapy, and combination treatment have expanded the approaches used to manage MCL.
Mantle cell lymphoma develops from B lymphocytes in the mantle zone of lymphoid follicles.
Most cases are associated with a genetic change called t(11;14), which causes increased production of cyclin D1 and contributes to uncontrolled cell growth.
MCL can follow different clinical patterns. Some people have relatively slow-growing disease, while others develop rapidly progressive lymphoma requiring prompt treatment.
Not every person requires immediate treatment.
For carefully selected individuals with slow-growing, asymptomatic disease, a healthcare team may recommend active surveillance with regular examinations and testing.
Treatment is generally considered when there is:
The decision is individualized according to the overall clinical picture.
Treatment for newly diagnosed MCL varies considerably.
Possible approaches include:
Younger and medically fit patients may sometimes receive more intensive treatment, while less intensive approaches may be favored for older adults or people with other health considerations.
Targeted medications have become an important component of MCL treatment.
One major group is Bruton tyrosine kinase (BTK) inhibitors, which interfere with signaling pathways that help malignant B cells survive.
Examples include:
Other targeted therapies may also be used depending on disease characteristics and treatment history.
Monoclonal antibodies can recognize proteins on lymphoma cells and help the immune system eliminate them.
Rituximab, an antibody targeting CD20, is commonly incorporated into treatment strategies for MCL.
Other immune-based approaches may be considered depending on whether the disease is newly diagnosed, relapsed, or resistant to previous treatment.
MCL can return after an initial response or become resistant to treatment.
Treatment for relapsed or refractory disease may include:
CAR T-cell therapy is an important treatment approach for certain people with relapsed or refractory MCL.
Stem cell transplantation may be considered for selected patients, particularly those who are medically fit and have disease that responds to initial treatment.
The procedure involves intensive therapy followed by infusion of stem cells to restore blood-forming cells.
Because transplantation carries significant risks, eligibility is carefully evaluated.
Regular monitoring helps determine whether treatment is working and whether complications are developing.
Follow-up may include:
Molecular or specialized laboratory testing may also be used in certain situations.
MCL therapies can cause side effects that vary depending on the medications used.
Possible problems include:
Supportive medications and monitoring can help manage many treatment-related complications.
Long-term management may involve a multidisciplinary team that includes hematologists, oncologists, transplant specialists, and supportive-care professionals.
Care may include:
Treatment plans may change as the disease responds or progresses.
Prompt medical evaluation is important if symptoms include:
These symptoms may indicate an infection, treatment complication, or disease progression.
Mantle cell lymphoma treatment has evolved substantially with the development of targeted therapies and cellular treatments. Depending on the disease pattern and individual circumstances, management may involve active surveillance, immunochemotherapy, BTK inhibitors, monoclonal antibodies, stem cell transplantation, or CAR T-cell therapy.